For many decades, T helper 2 (T H 2) cells have been considered to predominantly regulate the pathogenic manifestations of allergic asthma, such as IgE-mediated sensitization, airway hyperresponsiveness, and eosinophil infiltration. However, recent discoveries have significantly shifted our understanding of asthma from a simple T H 2 cell-dependent disease to a heterogeneous disease regulated by multiple T cell subsets, including T follicular helper (T FH ) cells. T FH cells, which are a specialized cell population that provides help to B cells, have attracted intensive attention in the past decade because of their crucial role in regulating antibody response in a broad range of diseases. In particular, T FH cells are essential for IgE antibody class-switching. In this review, we summarize the recent progress regarding the role of T FH cells and their signature cytokine interleukin (IL)-21 in asthma from mouse studies and clinical reports. We further discuss future therapeutic strategies to treat asthma by targeting T FH cells and IL-21.